1418 - A Refined Continuous Individualized Risk Index (CIRI2-CLL) for Accurately Predicting Outcomes after Limited-Duration CLL Therapy

Primary Author / Presenter(s)

CZ

Can Zhang

Statistician
University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group
Cologne, Nordrhein-Westfalen, Germany

Co-Author(s)

Othman Al-Sawaf, MD

Faculty of Medicine
Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital
Cologne, Germany
ME

Mohammad Esfahani, PhD

Stanford University
Stanford, California, United States
SR

Sandra Robrecht

Faculty of Medicine and University Hospital Cologne
Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital
Cologne, Nordrhein-Westfalen, Germany
Eugen Tausch, MD

Treating Physician and Research Fellow
Division of CLL, Department of Internal Medicine III, University Hospital Ulm
Ulm, Germany
AS

Anke Schilhabel, PhD

University of Schleswig-Holstein, Campus Kiel
Kiel, Schleswig-Holstein, Germany
MR

Matthias Ritgen, MD

Department of Internal Medicine II, Campus Kiel, University of Schleswig-Holstein, Kiel, Germany
Kiel, Germany
CS

Christof Schneider, MD

MD
Division of CLL, Department of Internal Medicine III, University Hospital Ulm
Ulm, Baden-Wurttemberg, Germany
MP

Martin Peifer

University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany
Cologne, Nordrhein-Westfalen, Germany
Arnon P. Kater, MD, PhD

Vice Chair, Hematologist & Principal Scientist
Department of Hematology, Amsterdam UMC, Cancer Center Amsterdam, University of Amsterdam, and HOVON
Amsterdam, Noord-Holland, Netherlands
JS

John Seymour, MBBS, PhD, FRACP

Director, Department of Haematology
Peter MacCallum Cancer Centre & Royal Melbourne Hospital
Melbourne, Victoria, Australia
YJ

Yanwen Jiang, PhD

Genentech
San Francisco, California, United States
Barbara Eichhorst, MD

Associate Professor, Consultant Hematologist
Department I of Internal Medicine, University Hospital of Cologne
Cologne, Germany
Stephan Stilgenbauer, MD

Professor of Medicine, Medical Director
Division of CLL, Internal Medicine III, Ulm University
Ulm, Baden-Wurttemberg, Germany
Michael Hallek, MD, PhD

Principal Investigator, Director of Department I of Internal Medicine
German CLL Study Group, University Hospital of Cologne
Cologne, Germany
AA

Ash Alizadeh, MD, PhD

Stanford Cancer
Stanford, CA, United States
DK

David Kurtz, MD, PhD

Stanford University, Foresight Diagnostics
Stanford, California, United States
Kirsten Fischer

Faculty of Medicine and University Hospital Cologne
Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital
Department I of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, University Hospital Cologne and University of Cologne
Cologne, Nordrhein-Westfalen, Germany